Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 7
2018 11
2019 8
2020 7
2021 9
2022 6
2023 13
2024 8
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
The role of platelets in immune-mediated inflammatory diseases.
Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. Scherlinger M, et al. Nat Rev Immunol. 2023 Aug;23(8):495-510. doi: 10.1038/s41577-023-00834-4. Epub 2023 Jan 27. Nat Rev Immunol. 2023. PMID: 36707719 Free PMC article. Review.
Advances in the treatment of systemic lupus erythematosus.
Scherlinger M, Kolios AGA, Kyttaris VC, Tsokos GC. Scherlinger M, et al. Nat Rev Drug Discov. 2025 Jul 17. doi: 10.1038/s41573-025-01242-0. Online ahead of print. Nat Rev Drug Discov. 2025. PMID: 40676245 Review.
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Forcade E, Meyer A, Jorgensen C, Bigenwald C, Cornec D, Sibilia J, Choquet S, Martin T, Belot A, Jouret M, Bitoun S, Amoura Z, Hermine O, Mariette X, Donnadieu E, Avouac J; Club for Innovative Immunotherapies in Immune-mediated Inflammatory diseases (C3I). Scherlinger M, et al. Lancet Rheumatol. 2025 Jun;7(6):e434-e447. doi: 10.1016/S2665-9913(24)00377-1. Epub 2025 Mar 26. Lancet Rheumatol. 2025. PMID: 40157379 Review.
Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis.
Scherlinger M, Guillotin V, Douchet I, Vacher P, Boizard-Moracchini A, Guegan JP, Garreau A, Merillon N, Vermorel A, Ribeiro E, Machelart I, Lazaro E, Couzi L, Duffau P, Barnetche T, Pellegrin JL, Viallard JF, Saleh M, Schaeverbeke T, Legembre P, Truchetet ME, Dumortier H, Contin-Bordes C, Sisirak V, Richez C, Blanco P. Scherlinger M, et al. Sci Transl Med. 2021 Jun 30;13(600):eabi4994. doi: 10.1126/scitranslmed.abi4994. Sci Transl Med. 2021. PMID: 34193612
New and future therapies: Changes in the therapeutic armamentarium for SLE.
Askanase A, Khalili L, Tang W, Mertz P, Scherlinger M, Sebbag E, Chasset F, Felten R, Arnaud L. Askanase A, et al. Among authors: scherlinger m. Best Pract Res Clin Rheumatol. 2023 Dec;37(4):101865. doi: 10.1016/j.berh.2023.101865. Epub 2023 Aug 24. Best Pract Res Clin Rheumatol. 2023. PMID: 37633826 Review.
French protocol for the diagnosis and management of systemic lupus erythematosus.
Amoura Z, Bader-Meunier B, Antignac M, Bardin N, Belizna C, Belot A, Bonnotte B, Bouaziz JD, Chasset F, Chiche L, Cohen F, Costedoat-Chalumeau N, Daugas E, Devilliers H, Diot E, Elefant E, Faguer S, Ferreira N, Hachulla E, Hanslik T, Hie M, Jourde-Chiche N, Le Guern V, Martin T, Mathian A, Michel M, Miyara M, Papo T, Richez C, Scherlinger M, Sibilia J, Uzunhan Y, Wahl D, Wojtasik G, Yelnik C; Collaborators; Collaborators. Amoura Z, et al. Among authors: scherlinger m. Rev Med Interne. 2024 Sep;45(9):559-599. doi: 10.1016/j.revmed.2024.07.006. Epub 2024 Aug 26. Rev Med Interne. 2024. PMID: 39191627 Free article. Review.
64 results